liver disease

FDA issues new warning on liver disease drugFDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
Unique clinic-pharmacy collaboration benefits hepatitis C patientsA Walgreens study sheds light on the benefits of patient-centered pharmacy-based programs.
How Pharmacists Are Helping Hep C Patients
How Pharmacists Are Helping Hep C PatientsA Walgreens study found that pharmacist collaboration helps Hep C patients with better outcomes and cheaper co-pays.
FDA approves novel leukemia, hepatitis C drugsFDA approved the first treatment for patients with a certain type of acute myeloid leukemia, as well as 2 new drugs to treat hepatitis C.
One-step test screens for hepatitis C virus infectionsAn easy, cost-effective, one-step test can allow clinicians to screen, detect, and confirm hepatitis C virus (HCV) infections, according to a new study.
Guideline: Patients with liver disease should be first to receive expensive Hep C drugsPatients with advanced liver disease or other severe symptoms of hepatitis C virus (HCV) infection should be first in line for drug therapy, according to a new guideline from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
Simeprevir approved for hepatitis C virusFDA has approved simeprevir (Olysio, Janssen Therapeutics) for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis.
Pediatric nonalcoholic fatty liver diseaseNonalcoholic fatty liver disease (NAFLD) in children is increasing, with studies showing it to be the most common liver abnormality in children aged 2 to 19 years.
FDA limits use of tolvaptan; irreversible liver damage possibleClinical trials find tolvaptan may cause injury leading to liver transplant or death
From the American College of Gastroenterology Annual Scientific Meeting: Know your options for cost-effective management of HEThe economic implications of HE are numerous and marked altered as based upon direct and indirect costs, worsening of patient's and patient's family members quality of life, employment status, and autonomy.